Meridian Medical Technologies—the global health security subsidiary of CDMO Kindeva—just secured a major contract, worth up to a potential $226 million, with the DoD's Defense Logistics Agency to shore up U.S. countermeasures against chemical attack.
Per the commitment, Kindeva will supply up to 3 million units of its chemical nerve agent antidote autoinjector to the DLA, which handles procurement and distribution of resources to the Army, Navy, Air Force, Marine Corps and other federal agencies.
The Antidote Treatment-Nerve Agent Autoinjectors (ATNAA) at the center of the contract represent the military-grade version of Kindeva's civilian product DuoDote. Both devices deliver atropine and pralidoxime chloride, an antidote to organophosphate nerve agents and insecticides used in chemical warfare, through a self-administered dual-chamber autoinjector.
According to Kindeva, the two devices are the only self-administered combination treatment approved by the FDA to treat organophosphate poisoning.
“We are thrilled to announce our new partnership with the DLA as Kindeva continues to support the U.S. government in addressing evolving global security threats,” said David Stevens, CEO of Kindeva, in a statement. “This contract reflects Kindeva’s longstanding dedication to manufacturing high-quality, reliable treatments that help protect military personnel and civilian communities alike.”
The DLA accord follows a previous $129 million contract, finalized in late 2025, to supply the civilian version of the autoinjector, DuoDote, to the Strategic National Stockpile (SNS), a supply of emergency treatments managed by the U.S. Department of Health and Human Services’ Administration for Strategic Preparedness and Response (ASPR).
Kindeva isn't the only pharma to receive a recent boost by way of a chemical defense contract.
Last week, ASPR’s Biomedical Advanced Research and Development Authority (BARDA) issued a $96 million grant to help along development of an organophosphate antidote by Kaléo. In contrast to Kindeva's atropine-pralidoxime chloride combination, Kaléo’s autoinjector delivers pralidoxime alone.
The BARDA funding will go toward late-stage development of Kaléo’s autoinjector, manufacturing validation, FDA regulatory approval, and the initial procurement of the auto-injectors for national stockpiles.